Groundbreaking research has confirmed that Pittsburgh Compound B binds to the beta-amyloid deposits in the brains of patients with Alzheimer's disease. The finding is a major step toward an early, definitive diagnosis of the memory-stealing condition.
Groundbreaking research has confirmed that Pittsburgh Compound B binds to the beta-amyloid deposits in the brains of patients with Alzheimer's disease. The finding is a major step toward an early, definitive diagnosis of the memory-stealing condition.
"As excited as researchers get, we are pretty excited," said senior author Dr. Steven T. DeKosky, director of the Alzheimer's Disease Research Center at the University of Pittsburgh.
DeKosky and colleagues studied a 63-year-old woman with a clinical diagnosis of AD who underwent PIB-PET imaging and brain autopsy upon her death 10 months later. The regions of her brain with the highest PIB levels before death correlated precisely with those with high beta-amyloid plaque concentration postmortem. An additional 27 brain autopsies confirmed the findings, which investigators reported in the March 12 online issue of Brain.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Mammography Study: AI Facilitates Greater Accuracy and Longer Fixation Time on Suspicious Areas
July 8th 2025While noting no differences in sensitivity, specificity or reading time with adjunctive AI for mammography screening, the authors of a new study noted a 4 percent higher AUC and increased fixation time on lesion regions.
Can Contrast-Enhanced Mammography be a Viable Screening Alternative to Breast MRI?
June 17th 2025While the addition of contrast-enhanced mammography (CEM) to digital breast tomosynthesis (DBT) led to over a 13 percent increase in false positive cases, researchers also noted over double the cancer yield per 1,000 women in comparison to DBT alone.
Contrast-Enhanced Mammography and High-Concentration ICM Dosing: What a New Study Reveals
June 16th 2025New research showed a 96 to 97 percent sensitivity for contrast-enhanced mammography (CEM) with an increased iodine delivery rate facilitating robust contrast enhancement for women with aggressive breast cancer.